Topical steroid risk analysis: Differentiating between physiologic and pathologic adrenal suppression
Authors:
- 30 October 2013
- journal article
- review article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 25 (6) , 501-506
Abstract
Topical corticosteroids are a mainstay of therapy for inflammatory skin disorders. Hypothalamic-pituitary-adrenal (HPA) axis suppression is a potential systemic risk of topical steroid use. Our aim was to review available data on the risk of HPA axis suppression associated with long-term topical steroid use and to distinguish between pathologic and physiologic adrenal suppression. We performed a PubMed search for literature that evaluated the risk of HPA axis suppression associated with topical steroid use. Fifteen of sixteen clinical trials reviewed did not report any pathologic adrenal suppression. In the single clinical trial that reported pathologic adrenal suppression, the patients used twice the maximum recommended amount of clobetasol propionate continuously for as long as 18 months. Physiologic adrenal suppression was seen as early as 1-2 weeks after treatment with class I-IV topical corticosteroids. In about half of these patients, cortisol levels spontaneously returned to normal within a few weeks, despite continuous therapy. Even when adrenal suppression occurs, topical corticosteroids are unlikely to be associated with clinical signs or symptoms of HPA axis suppression and are extremely safe as long as they are used within the current safety guidelines.Keywords
This publication has 38 references indexed in Scilit:
- Cushing's syndrome caused by mucosal corticosteroid therapyInternational Journal of Dermatology, 2008
- Henoch-Schönlein purpura associated with Proteus mirabilis urinary tract infectionJournal of the American Academy of Dermatology, 2008
- Cushing Syndrome Caused by Topical Corticosteroid: A Case ReportThe American Journal of the Medical Sciences, 2007
- Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accusedBritish Journal of Dermatology, 2007
- Topical fluticasone propionate lotion does not cause HPA axis suppressionThe Journal of Pediatrics, 2006
- Adverse effects of topical glucocorticosteroidsJournal of the American Academy of Dermatology, 2006
- A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasisJournal of the American Academy of Dermatology, 1991
- Superpotent topical steroid treatment of psoriasis vulgaris—clinical efficacy and adrenal functionJournal of the American Academy of Dermatology, 1987
- Iatrogenic hyperadrenocorticism during topical steroid therapy: Assessment of systemic effects by metabolic criteriaJournal of the American Academy of Dermatology, 1982
- Regional Variation in Percutaneous Penetration of 14C Cortisol in Man**From the Division of Dermatology, Department of Medicine, University of California School of Medicine, San Francisco, California 94122.Journal of Investigative Dermatology, 1967